TUESDAY, Aug. 2 (HealthDay News) -- There's still no cure for
the common cold, but there may be a way to shorten its misery: A
new study suggests that higher doses of zinc lozenges in certain
formulations may cut the length of colds by more than 40
Researcher Dr. Harri Hemila, of the University of Helsinki in
Finland, reviewed 13 placebo-controlled trials examining the effect
of zinc lozenges on cold infections. Three of them found that zinc
acetate in daily doses of more than 75 milligrams (mg) shortened
colds' duration by 42 percent, on average.
Five trials using zinc salts other than acetate in daily doses
greater than 75 mg shortened colds by an average of 20 percent,
while another five using less than 75 mg per day produced no
"Much of the variation in the published study findings can be explained by the daily dose of zinc administered in the zinc lozenges," said Hemila, who funded the research himself. "When focusing on those studies which have used large daily doses of zinc, there is strong evidence that zinc lozenges shorten the duration of colds."
The study is published in
The Open Respiratory Medicine Journal.
Despite the popularity of zinc supplements, controversy over
their effectiveness has continued since a much-publicized 1984
study first suggested a cold-limiting effect. Allowing the lozenge
to dissolve instead of swallowing it seemed to provide a
therapeutic effect. Since then, more than a dozen studies have been
carried out, but data on the trace mineral's effectiveness has been
All of the trials examined by Hemila compared zinc lozenges to
placebos. While surprised to note how strong the correlation was
between daily doses of zinc and its effect on colds' duration, he
said he and his colleagues still don't know why it seems to
"In the evidence-based medicine framework, we are primarily interested in the question whether there is an effect, and how great, whereas the mechanism of the effect is a secondary issue," he said.
No prior studies showed zinc lozenge use -- even up to 150 mg
per day -- might cause harm aside from bad taste or constipation,
Hemila said, and the most recent trial on zinc acetate indicated no
significant differences between zinc and placebo groups in adverse
effects even though the daily zinc dose was 92 mg.
Dr. Lisa Winston, an epidemiologist at San Francisco General
Hospital, praised the study as a "pretty good synthesis of the
data," although she noted that the trials Hemila reviewed involved
small numbers of participants.
"It's an area of controversy and question . . . but I don't think the evidence is strong enough, nor do I think the author is suggesting, that we can base clinical practice on it," said Winston, also an associate professor in the University of California-San Francisco Department of Medicine. "I would tell my patients we still don't have a cure [for the common cold], and we don't know if zinc works."
The U.S. National Library of Medicine has more about the